The use of biomaterials in delivering CRISPR/Cas9 for gene therapy in infectious diseases
holds tremendous potential. This innovative approach combines the advantages of …

Cystic fibrosis (CF) is a complex genetic respiratory disorder that necessitates innovative
gene delivery strategies to address the mutations in the gene. This review delves into the …

Abstract Approximately 10% of Cystic Fibrosis (CF) patients, particularly those with CF
transmembrane conductance regulator (CFTR) gene nonsense mutations, lack effective …

The in vivo efficacy of polymeric nanoparticles (NPs) is dependent on their
pharmacokinetics, including time in circulation and tissue tropism. Here we explore the …

Cystic fibrosis (CF) is a progressive, genetic, multi‐organ disease affecting the respiratory,
digestive, endocrine, and reproductive systems. CF can affect any aspect of the …

Cystic fibrosis (CF) is a monogenic recessive genetic disorder caused by mutations in the
CF Transmembrane-conductance Regulator gene (CFTR). Remarkable progress in basic …

The importance of non-canonical DNA structures such as G-quadruplexes (G4) and
intercalating-motifs (iMs) in the fine regulation of a variety of cellular processes has been …

Cytosolic delivery of bioactive agents has exhibited great potential to cure undruggable
targets and diseases. Because biological cell membranes are a natural barrier for living …

Non-viral nanoparticles (NPs) have seen heightened interest as a delivery method for a
variety of clinically relevant nucleic acid cargoes in recent years. While much of the focus …

Recent developments in artificial nucleic acid and drug delivery systems present
possibilities for the symbiotic engineering of therapeutic oligonucleotides, such as antisense …